Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 105, Issue 4, 2017, Pages 497-505

  Martínez, Carmen ^a   Millán, Olga ^a   Rovira, Montserrat ^a   Fernández Avilés, Francesc ^a   López, Anna ^a   Suárez Lledó, María ^a   Carreras, Enric ^a   Urbano Ispízua, Álvaro ^a   Brunet, Mercè ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Allogeneic stem cell transplantation; Graft versus host disease; Pharmacodynamics; T effector cells; Treg cells

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; CD3 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; GAMMA INTERFERON; INTERLEUKIN 2; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; STEROID; TUMOR NECROSIS FACTOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG MECHANISM; EFFECTOR CELL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PHARMACODYNAMICS; PILOT STUDY; REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; SENSITIVITY AND SPECIFICITY; ALLOGRAFT; BLOOD; CD4 CD8 RATIO; DRUG MONITORING; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; T LYMPHOCYTE;

ADULT; AGED; ALLOGRAFTS; BIOMARKERS; CD4-CD8 RATIO; DRUG MONITORING; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PILOT PROJECTS; T-LYMPHOCYTES;

EID: 84996656643     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-016-2145-5     Document Type: Article

References (35)

1. Choi SW, Reddy P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol. 2014;11:536–47.
2. Ruutu, T. Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014;49:168–74.
3. Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47:1459–64.
4. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc. 2004;36(S1):S378–91.
5. Wood A, Maurer G, Neiderberger W, Beveridge T. Cyclosporine; pharmacokinetics, metabolism and drug interactions. Transplant Proc. 1983;15:2409–12.
6. Atkinson K, Biggs JC, Britton K, Short R, Mrongovius R, Concannon A, et al. Oral administration of cyclosporine A for recipients of allogeneic marrow transplantation: implications of clinical gut dysfunction. Br J Haematol. 1984;56:223–31.
7. Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T, et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol. 2007;47:6–12.
8. Bullingham RE, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36:315–24.
9. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429–55.
10. Jenke A, Renner U, Richte M, Freberg-Richter J, Platzbecker U, Helwig A, et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant. 2001;15:176–84.
11. Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant. 2001;27:1255–62.
12. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methetrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant. 2005;35:1089–93.
13. Millán O, Brunet M, Campistol JM, Faura A, Rojo I, Vidal E, et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem. 2003;49:1891–9.
14. Brunet M, Campistol JM, Diekmann F, Guillén D, Millán O. T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diag Ther. 2007;11:247–56.
15. Millán O, Benitez C, Guillén D, López A, Rimola A, Sánchez-Fueyo A, et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol. 2010;137:337–46.
16. Millán O, Rafael-Valdivia L, Torrademé E, López A, Fortuna V, Sánchez-Cabus S, et al. Intracellular IFN-γ and IL2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug exposure in the novo liver transplant recipients. Cytokine. 2013;61:556–66.
17. Grinyo JM, Ekberg H, Richard D, Richard D. Mamelok RD, Oppenheimer F, Sánchez-Plumed J, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009;24:2269–76.
18. Fujioka T, Tamaki H, IkegameK Yoshihara S, Taniguchi K, Kaida K, et al. Frequency of CD4+ FOXP3+ regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant. 2013;48:859–64.
19. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, et al. Frequency of CD41CD25hiFOXP31 regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2010;16:907–14.
20. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;108:1291–7.
21. Pala P, Hussell T, Openshaw PJ, et al. Flow cytometric measurement of intracellular cytokines. J Immunol Methods. 2000;243:107–24.
22. Godoy-Ramirez K, Frank K, Mahdavifar S, Andersson L, Gaines H. Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry. J Immunol Methods. 2004;292:1–15.
23. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–50.
24. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389–99.
25. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003;9:243–56.
26. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–9.
27. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401–6.
28. Ratajczak P, Janin A, Peffault de Latour R, Leboeuf C, Desveaux A, Keyvanfar K, et al. Th17/Treg ratio in human graft-versus-host disease. Blood. 2012;116:1165–71.
29. Kobashigawa J, Kiyosaki K, Patel J, Kittleson M, Kubak B, Davis S, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant. 2010;29:504–8.
30. Cadillo-Chavez R, Echegaray S, Santiago-Delpin EA, Rodríguez-Trinidad AT, Camacho-Carrazo B, Alfaro T, et al. Assessing the risk of infection and rejection in hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc. 2006;38:918–20.
31. Thai NL, Blisard D, Tom K, Basu A, Smetanka C, Tan H, et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: correlation between low T-cell responses and infection. Transplantation. 2006;82:1649–52.
32. Zeevi A, Britz JA, Bentlejewski CA, Guaspari D, Tong W, Bond G, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transplant Immunol. 2005;15:17–24.
33. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663–8.
34. 7R. Nat Med. 2010;16:1434–9.
35. Millán O, Rafael-Valdivia L, San Segundo D, Boix F, Castro-Panete MJ, López-Hoyos M, et al. Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplants? Results of a multicentric study. Clinical Immunol. 2014;154:141–54.